Navigation Links
Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
Date:8/20/2008

Moore Labriola LLP and The Schmidt Firm, LLP represent Virginia man who developed pancreatitis; FDA seeks more stringent warnings.

San Diego, CA (PRWEB) August 20, 2008 -- A Virginia man yesterday filed what is believed to be the first personal injury lawsuit stemming from injuries associated with the use of http://www.schmidtandclark.com/Byetta/ [Byetta]®, an injectable medication for diabetes. Victor Deleon alleges in a lawsuit filed in San Diego Superior Court (Case No. 37-2008-00090003-CU-PL-CTL) that the manufacturer of the drug, San Diego-based Amylin Pharmaceuticals, Inc., and the drug's co-marketer, Eli Lilly and Company, failed to adequately test and monitor the http://www.schmidtandclark.com/Byetta-Side-Effects/ [side effects of Byetta]®, and didn't warn doctors or patients of the risk of developing http://www.schmidtandclark.com/Byetta-Pancreatitis/ [pancreatitis]. Deleon was hospitalized in December of 2007 after developing the condition, which causes inflammation of the pancreas and can lead to bleeding and death.
        
Deleon's lawsuit comes two days after the Food and Drug Administration (FDA) announced that it has received six reports of hemorrhagic or necrotizing pancreatitis in patients taking Byetta® since October of 2007. Two of the six patients died. In a press release, the FDA said it is "working with the maker of http://moorelabriola.injuryhelpnetwork.com/byetta/ [Byetta]®" to add "stronger and more prominent warnings" to the product's label.

Deleon's lawsuit alleges that Amylin "failed to adequately warn prescribing physicians of the risk of pancreatitis, of measures needed to properly assess the appropriateness of prescribing the drug to certain categories of patients, and of measures doctors and patients could and should take to minimize the risk."

In the fall of 2007, Amylin agreed to add information about pancreatitis to the "precautions" section of the Byetta® label after the FDA reported 30 post-marketing reports of acute pancreatitis associated with the drug.

"It is pretty obvious that the label change in 2007 was not adequate," said Thomas M. Moore of http://moorelabriola.injuryhelpnetwork.com/ [Moore Labriola LLP] in Newport Beach, who jointly represents Mr. Deleon with Michael Schmidt of http://www.schmidtlaw.com/ [The Schmidt Firm, LLP] in Dallas, TX. "We believe that Amylin possessed data prior to the 2007 label revision that justified a stronger and more prominent warning than the precaution language that Amylin ultimately negotiated with FDA," Moore added.        

Contact:
Laci Thomas
The Schmidt Firm, LLP
Lthomas @ schmidtlaw.com
http://www.schmidtlaw.com
(866) 920-0753

###

Read the full story at http://www.prweb.com/releases/schmidt_law/Byetta/prweb1229814.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Amylin Pharmaceuticals Reports First Quarter Financial Results
2. Amylin Pharmaceuticals Reports 2007 Financial Results
3. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
4. Amylin Pharmaceuticals to Present at Research & Development Day
5. Amylin Pharmaceuticals to Webcast Conference Call
6. Amylin Pharmaceuticals to Webcast Third Quarter Results
7. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
8. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
9. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
10. Alseres Pharmaceuticals, Inc. Reports Second Quarter 2008 Operational and Financial Results
11. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... FRANCE (PRWEB) , ... January 21, 2017 , ... ... the Indian Ocean, isolated from the rest of the world with ZANZIBAR SHOWER GEL. ... Africa, Phytocéane used key ingredients, Virgin Coconut Oil and moisturizing vegetal coral to create ...
(Date:1/21/2017)... ... January 21, 2017 , ... In the United States, 20 million women ... of recovery, they often feel shame for having struggled with an eating disorder as ... the workshop, “Rising Strong in Life After an Eating Disorder” -- to be featured ...
(Date:1/20/2017)... Texas (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... the bible in homes across the world. Yisrayl says this generation is a time like ... is to turn to the Bible. , Yisrayl says he does not want to sound ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Lice Troopers, the ... cases in families with school-aged children since the holiday season. , “It happens ... with their families, sharing hugs and taking photos, which is the head-to-head gateway that ...
(Date:1/20/2017)... ... 20, 2017 , ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions ... said Christina Austin - CEO of Pixel Film Studios. , TransFlare 4K Mystique ... Mystique lens flare and light leak transitions have a very high-dynamic range for super ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ( ... treat mitochondrial dysfunction, today announced new additions to its ... as Chief Medical Officer, and Daniel Geffken ... that Jim Carr , Pharm.D. has been promoted ... are pleased to welcome Doug and Daniel to our ...
(Date:1/19/2017)... 19, 2017 James ... & Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to European ... touchONCOLOGY, an article by James Gilbart ...
(Date:1/19/2017)... , January 19, 2017 ... Otsuka in the Milner Therapeutics Consortium   ... in Cambridge   ... PFE ) as a partner to the ... Consortium, which enables the efficient transfer of materials between ...
Breaking Medicine Technology: